INIS
patients
100%
stem cells
34%
diseases
31%
risks
29%
lymphomas
24%
leukemia
23%
blood
20%
myeloid leukemia
19%
comparative evaluations
19%
transplants
17%
therapy
16%
populations
14%
data
13%
levels
11%
mortality
11%
malignancies
10%
grafts
10%
adults
10%
doses
9%
netherlands
9%
cancer
9%
chemotherapy
9%
refractories
9%
natural killer cells
8%
cyclophosphamide
8%
host
8%
hazards
8%
hemophilia
7%
tumors
7%
receptors
6%
glucose
6%
control
6%
humans
6%
induction
6%
toxicity
6%
transfusions
5%
plasma
5%
symptoms
5%
quality of life
5%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
35%
Maastricht
19%
Acute Myeloid Leukemia
16%
Working Party
12%
Marrow Transplantation
11%
Overall Survival
11%
Type 2 Diabetes Mellitus (T2DM)
10%
Confidence Interval
10%
Natural Killer Cells
10%
Graft-versus-host Disease (GvHD)
9%
Chronic Lymphocytic Leukemia
9%
Netherlands
9%
Hazard Ratio
8%
Leukemia Patients
7%
Unrelated Donor
6%
Acute Leukemia
6%
Lymphoma
6%
Multiple Myeloma
5%
Progression-free Survival
5%
Non-relapse Mortality
5%
European Society
5%
Malignancy
5%
Post-transplantation Cyclophosphamide (PTCy)
5%
Hemophilia
5%
First Complete Remission
5%
Medicine and Dentistry
Hematopoietic Cell
14%
Acute Myeloid Leukemia
13%
Cell Transplantation
12%
Overall Survival
11%
Maturity Onset Diabetes of the Young
9%
Diseases
9%
B-Cell Chronic Lymphocytic Leukemia
8%
Allogeneic Stem Cell Transplantation
7%
Autologous Stem Cell Transplantation
7%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Myelodysplastic Syndrome
6%
Hazard Ratio
6%
Cancer
6%
Progression Free Survival
5%
Cyclophosphamide
5%
Bleeding
5%